This week: BPC-157, the most talked-about healing peptide on the internet — a 15-amino-acid fragment from human gastric juice with thirty years of animal research and encouraging reports, but yet to be proven in human trials.

Jake and Cynthia unpack the mechanism (angiogenesis, fibroblast activity, gut-barrier repair), the striking tendon/ligament/gut data in animals, the real evidence gap, and the July 2026 FDA advisory vote everyone is misreading.

Plus the GLP pulse: the FDA's interim peptide-compounding policy names BPC-157, Europe's regulator backs Lilly's oral GLP-1 Foundayo, and Biomea posts Phase 1 data for its oral small-molecule BMF-650.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

**Sources:**

- Reuters — FDA/HHS submit interim peptide-compounding policy for White House review (Oct 15): https://www.reuters.com/legal/litigation/us

-fda-takes-step-change-peptide-compounding-policy-2026-10-15/

- AP via Stocktwits — BPC-157 named in compounding policy reporting; Hims stock +6% (Oct 15): https://stocktwits.com/news-articles/markets/equity/hims-stock-peptide-hopes-trump-administration-reviews-plan-unlock-market/cZx0VkeRBr8

- EMA — CHMP recommends EU approval for Foundayo/orforglipron (Oct 16): https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026

- Reuters — Lilly's Foundayo wins European backing (Oct 16): https://www.reuters.com/legal/litigation/eli-lillys-weight-loss-pill-wins-backing-europe-2026-10-16/

- GlobeNewswire — Biomea Phase 1 results for oral small-molecule GLP-1 BMF-650 (Oct 13): https://www.globenewswire.com/news-release/2026/10/13/3380154/0/en/biomea-fusion-announces-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist.html

- Brainflow — BPC-157 complete guide (2025 AAOS systematic review, 39 studies): https://brainflow.co/complete-guide-to-BPC-157-benefits-dosage/

- Marketing or Science — BPC-157 evidence vs hype, July 2026 PCAC vote: https://marketingorscience.com/articles/pharma/2026/07/BPC-157-healing-peptide

- Lambert Medical Practice — BPC-157 peptide guide (mechanisms, gut/tendon data): https://lambertmedicalpractice.co.uk/blog/BPC-157-peptide-guide/

- Top Doctor Magazine — PCAC vote 8–6, ulcerative colitis indication: https://topdoctormagazine.com/news/regenerative-medicine-peptide-evidence-hype/

- OneDayMD — clinician peptide guide (PCAC six-of-seven, regulatory status): https://www.onedaymd.com/2026/02/peptides-guide.html

- Frier Levitt — PCAC 503A legal analysis (advisory vs binding): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/

- Blog by Donna — PCAC vote explainer ("recommendation is not a rule"): https://blogbydonna.com/the-fda-peptide-vote-didnt-legalize-BPC-157/

A Spoke-Media production:

https://www.spoke-media.com

This week the biggest story isn't a trial readout — it's the economy reshaping itself around GLP-1s.

Jake and Cynthia unpack Gallup's new numbers (15% of US adults have tried a GLP-1 for weight loss, up from 3% two years ago), the Cornell grocery-receipts study (household spending down 5.3%, savory snacks down 10%), and the BCG survey (active users spending 11% more on high-protein foods). Plus the industry response: Olive Garden's Lighter Portions menu, Nestlé's GLP-1 nutrition line, and Walmart covering Ozempic and Mounjaro at zero cost for employees with type 2 diabetes in 2027.

Also: a Blood Cancer Journal study of 140,000 matched patients finds no blood-cancer risk signal from GLP-1s.

Semaglutide extends lifespan 12% in mice (Nature); Pharma's GLP-1 brain-drug pipeline heats up with Lilly's Brenipatide for alcohol use disorder; and the amylin wave builds with Petrelintide (10.7%), Survodutide (13.1%), and Trevogrumab's 70% muscle-loss prevention.

For research and informational purposes only — not medical advice.

**Sources:**

- Gallup — GLP-1 usage reaches new high (15% ever-used, 11% current; May–June 2026 survey): https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx

- Medical Xpress — Cornell/Journal of Marketing Research grocery spending study (Dec 2025): https://medicalxpress.com/news/2025-12-ozempic-foods-americans-buy.html

- Green Queen — BCG GLP-1 food consumption survey (+11% protein, +15% fruit/veg): https://www.greenqueen.com.hk/boston-consulting-group-glp-1-food-consumption-spending-protein-fiber-survey/

- Yahoo Lifestyle — Olive Garden "Lighter Portions" menu, GLP-1 users cited (Oct 13, 2026): https://www.yahoo.com/lifestyle/articles/restaurant-menus-getting-smaller-glp-160004125.html

- Mexico Business News — Novo Nordisk CEO on food industry rethink (Oct 12, 2026): https://mexicobusiness.news/health/news/glp-1-drugs-push-food-industry-rethink-portions-products

- WebProNews — GLP-1 drugs shrink appetites; food company earnings calls (Oct 12, 2026): https://www.webpronews.com/glp-1-drugs-shrink-appetites-and-grocery-bills-pharma-giants-reap-billions-while-snack-makers-scramble/

- Food Navigator — Nestlé developing GLP-1 nutrition products (Oct 8, 2026): https://www.foodnavigator.com/Article/2026/10/08/how-glp-1-weight-loss-drugs-are-reshaping-food-and-beverage-innovation/

- CNBC — Walmart $0 GLP-1s for T2D employees in 2027 (Oct 13, 2026): https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-employee-benefits.html

- Nature / Blood Cancer Journal — GLP-1RAs and hematologic malignancy risk, TriNetX matched cohort (Oct 12, 2026): https://www.nature.com/articles/s41408-026-01618-4

- CNN — Semaglutide extends lifespan in older mice, Nature study (Oct 13, 2026): https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging

- UC Berkeley — GLP-1 treatment extends lifespan in older healthy mice (Sept 2026): https://vcresearch.berkeley.edu/news/glp-1-treatment-extends-lifespan-older-healthy-mice.

- Nature — Pharma's GLP-1 brain-drug pipeline: brenipatide, KP405, Baseline Therapeutics (Oct 13, 2026): https://www.nature.com/articles/d41586-026-03252-3

- Pharmacy Times — Petrelintide Phase 2 ZUPREME-1: up to 10.7% at 42 weeks (Oct 6, 2026): https://www.pharmacytimes.com/view/petrelintide-yields-up-to-10-7-weight-loss-with-mild-gi-effects

- GlobeNewswire — Zealand Pharma: Survodutide SYNCHRONIZE-2 up to 13.1% at 76 weeks (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html

- GlobeNewswire — Regeneron: Trevogrumab COURAGE prevents 70% of GLP-1 muscle loss (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html

Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world.

Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid growth hormone releasing factor with a protective chemical cap, two Phase three trials, visceral fat down fourteen to eighteen percent, lean body mass up, liver fat down, and an FDA approval (Egrifta) with a formulation modernization: Egrifta WR, approved March 2025 and in pharmacies since September 2025.

Plus the honest limits: a narrow approved use, maintenance required, and long-term cardiovascular safety still an open file.

Also: the weekly GLP pulse — the growing evidence that GLP-1s curb drug and alcohol cravings (PBS NewsHour), plus new research on compulsive gambling and shopping (CBS News).

For research and informational purposes only — not medical advice.

Sources:

• PBS NewsHour — The evidence suggesting GLP-1s can curb drug and alcohol cravings (Oct 7, 2026): https://www.pbs.org/newshour/show/the-evidence-suggesting-glp-1s-can-curb-drug-and-alcohol-cravings

• CBS News — Doctor explains how GLP-1 drugs could help reduce gambling, shopping addiction (Oct 9, 2026): https://www.cbsnews.com/news/glp-1-drugs-wharton-study-impulsive-spending/

• Medscape — Tesamorelin reduces visceral fat in HIV-associated lipodystrophy (Phase 3 data): https://www.medscape.com/viewarticle/732450

• Theratechnologies / Drugs.com — FDA Approval for EGRIFTA WR (tesamorelin F8), March 25, 2025: https://www.drugs.com/newdrugs/theratechnologies-receives-fda-approval-egrifta-wr-tesamorelin-f8-excess-visceral-abdominal-fat-6482.html

• Theratechnologies — Availability of EGRIFTA WR, September 5, 2025: https://www.cbj.ca/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy/

• Stanley & Grinspoon — Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation (JAMA / PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/

• Peptpedia — Tesamorelin (Egrifta): FDA-Approved, Visceral Fat Data: https://peptpedia.org/peptide/tesamorelin

Sermorelin is having a moment.

Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included.

Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.

For research and informational purposes only — not medical advice.

Sources:

• Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research

• Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588

• Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/

• The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016

• Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively

• Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/

EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.

Stories this week:

(1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis and sleep apnea improvements — and TRIUMPH-2 in type 2 diabetes published in The Lancet; Lilly expects to file with the FDA by end of March 2027.

(2) Lilly's amylin + tirzepatide combo EloraTZP: 23.3% at 48 weeks heading to Phase 3, with a real tolerability question — plus the wider amylin stacking moment.

(3) Boehringer/Zealand's survodutide Phase 3 SYNCHRONIZE-2: 13.1% at 76 weeks, published in NEJM the same day.

(4) Novo's oral strategy: up to $2.6B for ex-China rights to Hengrui's weekly oral GLP-1/GIP, real-world data on switching to the Wegovy pill, and Wegovy liver-fat normalization.

(5) The FDA's warning letter to Empower Pharmacy over mass-produced compounded GLP-1s — its fourth. Plus a market check: LLY dipped on great news, NVO down ~24% YTD.

For research and informational purposes only — not medical advice.

**Sources:**
- Cardiac Wire — TRIUMPH-1 full Phase 3: https://cardiacwire.com/a-new-king-of-the-glp-1s-could-be-crowned/
- USA Today — TRIUMPH-2 / Lilly FDA filing plans: https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/30/retatrutide-glp-1-eli-lilly-weight-loss/92019663007/
- BioSpace — EloraTZP Phase 2b: https://www.biospace.com/drug-development/superior-weight-loss-blood-sugar-control-propel-lillys-amylin-gip-glp-1-combo-into-phase-3
- Zealand Pharma — SYNCHRONIZE-2: https://mfn.se/one/a/zealand-pharma/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes-a9e0d011
- Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
- Reuters — OCTANE real-world switching study: https://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
- Becker's Hospital Review — FDA warning letter to Empower Pharmacy: https://www.beckershospitalreview.com/pharmacy/fda-flags-sterility-concerns-at-major-glp-1-compounder/